LOW-DOSE CYCLOSPORINE FOR THE TREATMENT OF CROHNS-DISEASE

被引:231
作者
FEAGAN, BG
MCDONALD, JWD
ROCHON, J
LAUPACIS, A
FEDORAK, RN
KINNEAR, D
SAIBIL, F
GROLL, A
ARCHAMBAULT, A
GILLIES, R
VALBERG, B
IRVINE, EJ
机构
[1] UNIV ALBERTA,DEPT MED,DIV GASTROENTEROL,EDMONTON,AB,CANADA
[2] MCMASTER UNIV,DEPT MED,DIV GASTROENTEROL,HAMILTON,ON,CANADA
[3] QUEENS UNIV,DEPT MED,DIV GASTROENTEROL,KINGSTON K7L 3N6,ON,CANADA
[4] UNIV WESTERN ONTARIO,DEPT MED,LONDON,ON,CANADA
[5] UNIV WESTERN ONTARIO,DEPT EPIDEMIOL & BIOSTAT,LONDON,ON,CANADA
[6] MCGILL UNIV,DEPT MED,DIV GASTROENTEROL,MONTREAL,PQ,CANADA
[7] UNIV MONTREAL,FAC MED,MONTREAL H3C 3J7,PQ,CANADA
[8] UNIV TORONTO,DEPT MED,DIV GASTROENTEROL,TORONTO,ON,CANADA
[9] UNIV OTTAWA,DEPT MED,OTTAWA,ON,CANADA
[10] UNIV OTTAWA,DEPT EPIDEMIOL & COMMUNITY MED,OTTAWA,ON,CANADA
关键词
D O I
10.1056/NEJM199406303302602
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Long-term corticosteroid therapy for Crohn's disease is associated with important types of morbidity, such as osteoporosis. Safe and effective alternative treatments are required. Although a short-term benefit of cyclosporine in active Crohn's disease has been suggested, the long-term safety and efficacy of this treatment have not been established. Methods. We conducted a randomized, double-blind, placebo-controlled evaluation of the effect of 18 months of low-dose cyclosporine treatment on the course of Crohn's disease. Adult patients whose disease had been active within the previous two years were randomly assigned to receive cyclosporine (151 patients) or placebo (154 patients) in addition to their usual therapy. Randomization was stratified according to center and score on the Crohn's Disease Activity Index (193 patients had scores of 150 or less, and 112 had scores greater than 150). The primary outcome measure was clinically important worsening of Crohn's disease, defined as a 100-point increase in the Crohn's Disease Activity Index from the patient's base-line value. Secondary outcomes were the use of prednisone and 5-aminosalicylates, mean score on the Crohn's Disease Activity Index and mean quality-of-life score, and the need for surgery. Results. The condition of more patients worsened with cyclosporine than with placebo (91 of 151, or 60.3 percent, vs. 80 of 154, or 51.9 percent; P = 0.10). The median time to worsening of disease in patients receiving cyclosporine was 338 days, as compared with 492 days in patients receiving placebo (P = 0.25; relative risk, 1.22; 95 percent confidence interval, 0.86 to 1.72). Analyses of the mean Crohn's Disease Activity Index and quality-of-life scores and of the use of prednisone and 5-aminosalicylates also failed to demonstrate benefit. Conclusions. In our patient population, the addition of low-dose cyclosporine to conventional treatment for Crohn's disease did not improve symptoms or reduce requirements for other forms of therapy.
引用
收藏
页码:1846 / 1851
页数:6
相关论文
共 32 条
[1]   NATURE AND EXTENT OF GLOMERULAR INJURY INDUCED BY CYCLOSPORINE IN HEART-TRANSPLANT PATIENTS [J].
BERTANI, T ;
FERRAZZI, P ;
SCHIEPPATI, A ;
RUGGENENTI, P ;
GAMBA, A ;
PARENZAN, L ;
MECCA, G ;
PERICO, N ;
IMBERTI, O ;
REMUZZI, A ;
REMUZZI, G .
KIDNEY INTERNATIONAL, 1991, 40 (02) :243-250
[2]  
BEST WR, 1979, GASTROENTEROLOGY, V77, P843
[3]  
BEST WR, 1976, GASTROENTEROLOGY, V70, P439
[4]   A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL OF CYCLOSPORINE THERAPY IN ACTIVE CHRONIC CROHNS-DISEASE [J].
BRYNSKOV, J ;
FREUND, L ;
RASMUSSEN, SN ;
LAURITSEN, K ;
DEMUCKADELL, OS ;
WILLIAMS, N ;
MACDONALD, AS ;
TANTON, R ;
MOLINA, F ;
CAMPANINI, MC ;
BIANCHI, P ;
RANZI, T ;
DIPALO, FQ ;
MALCHOWMOLLER, A ;
THOMSEN, OO ;
TAGEJENSEN, U ;
BINDER, V ;
RIIS, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (13) :845-850
[5]  
COHEN J, 1988, STATISTICAL POWER AN
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]  
DIXON WJ, 1988, BMDP STATISTICAL SOF, V2
[8]   CYCLOSPORINE FOR PLAQUE-TYPE PSORIASIS - RESULTS OF A MULTIDOSE, DOUBLE-BLIND TRIAL [J].
ELLIS, CN ;
FRADIN, MS ;
MESSANA, JM ;
BROWN, MD ;
SIEGEL, MT ;
HARTLEY, AH ;
ROCHER, LL ;
WHEELER, S ;
HAMILTON, TA ;
PARISH, TG ;
ELLISMADU, M ;
DUELL, E ;
ANNESLEY, TM ;
COOPER, KD ;
VOORHEES, JJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (05) :277-284
[9]   RISK-FACTORS FOR CYCLOSPORINE-INDUCED NEPHROPATHY IN PATIENTS WITH AUTOIMMUNE-DISEASES [J].
FEUTREN, G ;
MIHATSCH, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (25) :1654-1660
[10]  
HANAUER SB, 1993, AM J GASTROENTEROL, V88, P646